Follow
Mattias Carlsten
Title
Cited by
Cited by
Year
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells
M Carlsten, NK Björkström, H Norell, Y Bryceson, T van Hall, ...
Cancer research 67 (3), 1317-1325, 2007
3062007
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells
M Carlsten, H Norell, YT Bryceson, I Poschke, K Schedvins, ...
The Journal of Immunology 183 (8), 4921-4930, 2009
2922009
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
RW Childs, M Carlsten
Nature reviews Drug discovery 14 (7), 487-498, 2015
2632015
Natural killer cell-mediated immunosurveillance of human cancer
KJ Malmberg, M Carlsten, A Björklund, E Sohlberg, YT Bryceson, ...
Seminars in immunology 31, 20-29, 2017
2562017
IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
KJ Malmberg, V Levitsky, H Norell, CT De Matos, M Carlsten, K Schedvins, ...
The Journal of clinical investigation 110 (10), 1515-1523, 2002
2542002
Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications
M Carlsten, RW Childs
Frontiers in immunology 6, 144607, 2015
2282015
Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML
AT Björklund, M Carlsten, E Sohlberg, LL Liu, T Clancy, M Karimi, ...
Clinical Cancer Research 24 (8), 1834-1844, 2018
1782018
Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma
M Carlsten, N Korde, R Kotecha, R Reger, S Bor, D Kazandjian, ...
Clinical Cancer Research 22 (21), 5211-5222, 2016
1672016
The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
T Dosani, M Carlsten, I Maric, O Landgren
Blood cancer journal 5 (4), e306-e306, 2015
1422015
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
N Korde, M Carlsten, MJ Lee, A Minter, E Tan, M Kwok, E Manasanch, ...
Haematologica 99 (6), e81, 2014
1342014
Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype
C Fauriat, S Andersson, AT Bjorklund, M Carlsten, M Schaffer, ...
The Journal of Immunology 181 (9), 6010-6019, 2008
1332008
Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells
M Carlsten, M Järås
Frontiers in immunology 10, 489241, 2019
1322019
The core promoter of human thioredoxin reductase 1: cloning, transcriptional activity, and Oct-1, Sp1, and Sp3 binding reveal a housekeeping-type promoter for the AU-rich …
AK Rundlöf, M Carlsten, ESJ Arnér
Journal of Biological Chemistry 276 (32), 30542-30551, 2001
1282001
Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers
S Ito, CM Bollard, M Carlsten, JJ Melenhorst, A Biancotto, E Wang, J Chen, ...
Molecular therapy 22 (7), 1388-1395, 2014
1262014
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
KJ Malmberg, YT Bryceson, M Carlsten, S Andersson, A Björklund, ...
Cancer Immunology, Immunotherapy 57, 1541-1552, 2008
1232008
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome
M Carlsten, BC Baumann, M Simonsson, M Jädersten, AM Forsblom, ...
Leukemia 24 (9), 1607-1616, 2010
1172010
Efficient mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC against lymphoma and targets NK cell migration …
M Carlsten, E Levy, L Li, MV Peshwa, RW Childs
Frontiers in immunology 7, 177581, 2016
1072016
Coordinated expression of DNAM-1 and LFA-1 in educated NK cells
M Enqvist, EH Ask, E Forslund, M Carlsten, G Abrahamsen, V Béziat, ...
The Journal of Immunology 194 (9), 4518-4527, 2015
1022015
Sugar free: novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer
J Daly, M Carlsten, M O'Dwyer
Frontiers in immunology 10, 437588, 2019
912019
Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific …
H Norell, M Carlsten, T Ohlum, KJ Malmberg, G Masucci, K Schedvins, ...
Cancer research 66 (12), 6387-6394, 2006
802006
The system can't perform the operation now. Try again later.
Articles 1–20